{"id":"darolutamide","rwe":[{"pmid":"41895750","year":"2026","title":"Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer.","finding":"","journal":"Anticancer research","studyType":"Clinical Study"},{"pmid":"41886076","year":"2026","title":"Vigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"41851476","year":"2026","title":"Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.","finding":"","journal":"Prostate cancer and prostatic diseases","studyType":"Clinical Study"},{"pmid":"41840025","year":"2026","title":"Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41815147","year":"2026","title":"Neoadjuvant androgen deprivation therapy with bicalutamide compared to hormonal agents in treating high-risk prostate cancer: a real-world cohort study.","finding":"","journal":"Translational cancer research","studyType":"Clinical Study"}],"_fda":{"id":"fd96ab4c-d7f4-446f-93d8-1dae246a450a","set_id":"1a7cb212-56e4-4b9d-a73d-bfee7fe4735e","openfda":{"unii":["X05U0N2RCO"],"route":["ORAL"],"rxcui":["2180330","2180336"],"spl_id":["fd96ab4c-d7f4-446f-93d8-1dae246a450a"],"brand_name":["NUBEQA"],"spl_set_id":["1a7cb212-56e4-4b9d-a73d-bfee7fe4735e"],"package_ndc":["50419-395-01","50419-395-72"],"product_ndc":["50419-395"],"generic_name":["DAROLUTAMIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DAROLUTAMIDE"],"manufacturer_name":["Bayer HealthCare Pharmaceuticals Inc."],"application_number":["NDA212099"],"is_original_packager":[true]},"version":"23","pregnancy":["8.1 Pregnancy Risk Summary The safety and efficacy of NUBEQA have not been established in females. Based on its mechanism of action, NUBEQA can cause fetal harm and loss of pregnancy [see Clinical Pharmacology (12.1) ]. Animal embryo-fetal developmental toxicology studies were not conducted with darolutamide. There are no human data on the use of NUBEQA in pregnant females."],"overdosage":["10 OVERDOSAGE There is no known specific antidote for darolutamide overdose. The highest dose of NUBEQA studied clinically was 900 mg twice daily, equivalent to a total daily dose of 1800 mg. No dose limiting toxicities were observed with this dose. Considering the saturable absorption and the absence of evidence for acute toxicity, an intake of a higher than recommended dose of darolutamide is not expected to lead to systemic toxicity in patients with intact hepatic and renal function [see Clinical Pharmacology (12.3) ] . In the event of intake of a higher than recommended dose in patients with severe renal impairment or moderate hepatic impairment, if there is suspicion of toxicity, interrupt NUBEQA treatment and undertake general supportive measures until clinical toxicity has been diminished or resolved. If there is no suspicion of toxicity, NUBEQA treatment can be continued with the next dose as scheduled."],"description":["11 DESCRIPTION NUBEQA is an androgen receptor inhibitor. The chemical name is N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide. The molecular weight is 398.85 and the molecular formula is C 19 H 19 Cl N 6 O 2 . The structural formula is: Darolutamide is an optically active with a specific rotation value [α] 20 D = 72.2 o *mL/(dm*g), white to greyish- or yellowish white crystalline powder, that is soluble in tetrahydrofuran, but practically insoluble in aqueous medium. Darolutamide has a pKa of 11.75. NUBEQA (darolutamide) is supplied as film-coated tablets containing 300 mg of darolutamide for oral use. The inactive ingredients of the tablet are: calcium hydrogen phosphate, croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K 30, hypromellose 15 cP, macrogol 3350, and titanium dioxide. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied NUBEQA (darolutamide) 300 mg film-coated tablets are white to off-white, oval shaped tablets, marked with \"300\" on one side, and \"BAYER\" on the other side. NUBEQA 300 mg tablets are available in bottles of 120 tablets. NDC 50419-395-01 Storage and Handling Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature] . Keep the bottle tightly closed after first opening."],"geriatric_use":["8.5 Geriatric Use Of the 954 patients who received NUBEQA in ARAMIS, 88% of patients were 65 years and over, and 49% were 75 years and over. Of the 445 patients who received NUBEQA in ARANOTE, 74% of patients were 65 years and over, and 30% were 75 years and over. Of the 652 patients who received NUBEQA in ARASENS, 63% of patients were 65 years and over, and 16% were 75 years and over. No overall differences in safety or efficacy were observed between these patients and younger patients in both studies."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of NUBEQA in pediatric patients have not been established."],"effective_time":"20250603","clinical_studies":["14 CLINICAL STUDIES Non-Metastatic Castration Resistant Prostate Cancer ARAMIS (NCT02200614) was a multicenter, double-blind, placebo-controlled clinical trial in 1509 patients with non-metastatic castration resistant prostate cancer with a prostate-specific antigen doubling time (PSADT) of ≤ 10 months. Randomization was stratified by PSADT and use of bone-targeted therapy at study entry. Patients with pelvic lymph nodes less than 2 cm in short axis below the aortic bifurcation were eligible to enter the study. Absence or presence of metastasis was assessed by blinded independent central review (BICR). PSA results were not blinded and were not used for treatment discontinuation. Patients were randomized 2:1 to receive either 600 mg NUBEQA orally twice daily (n=955) or matching placebo (n=554). Treatment continued until radiographic disease progression as assessed by CT, MRI, 99m Tc bone scan by BICR, unacceptable toxicity or withdrawal. All patients received a gonadotropin-releasing hormone (GnRH) analog concurrently or had a bilateral orchiectomy. The median age was 74 years (range 48–95) and 9% of patients were 85 years of age or older. The racial distribution included 79% White, 13% Asian, 3% Black or African American, while ethnicity included 3.1% Hispanic or Latino patients. A majority of patients (73%) had a Gleason score of 7 or higher at diagnosis. The median PSADT was 4.5 months. Forty-two percent of patients in both treatment arms had prior surgery or radiotherapy to the prostate. Eleven percent of patients had enlarged pelvic lymph nodes less than 2 cm at study entry. Six percent of patients were retrospectively identified by BICR as having metastases at baseline. Seventy-three percent of patients received prior treatment with an anti-androgen (bicalutamide or flutamide). All patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 at study entry. At baseline, 47% of patients reported no pain on the Brief Pain Inventory-Short Form (a 7-day diary average of the daily worst pain item). There were 12 patients (1.3%) enrolled on the NUBEQA arm with a history of seizure. The major efficacy endpoint was metastasis free survival (MFS), defined as the time from randomization to the time of first evidence of BICR-confirmed distant metastasis or death from any cause within 33 weeks after the last evaluable scan, whichever occurred first. Distant metastasis was defined as new bone or soft tissue lesions or enlarged lymph nodes above the aortic bifurcation. Overall survival (OS), time to pain progression, and time to initiation of cytotoxic chemotherapy, were additional efficacy endpoints. Treatment with NUBEQA resulted in a statistically significant improvement in MFS compared to placebo. At the protocol-specified final analysis of OS, treatment with NUBEQA resulted in a statistically significant improvement in OS compared to placebo. The final analysis of OS and time to initiation of cytotoxic chemotherapy was event-driven and conducted after 254 OS events had occurred. The efficacy results from ARAMIS are summarized in Table 7 and Figure 1. Table 7: Efficacy Results from the ARAMIS Study NUBEQA (N=955) Placebo (N=554) NR: not reached Metastasis-free survival Locoregional-only progression occurred in 6% of patients overall. Distant Metastasis or Death (%) 221 (23) 216 (39) Median, months (95% CI) Based on Kaplan-Meier estimates 40.4 (34.3, NR) 18.4 (15.5, 22.3) Hazard Ratio (95% CI) Hazard ratio is based on a stratified Cox regression model. Hazard ratio < 1 favors NUBEQA. 0.41 (0.34, 0.50) P-value The pre-specified final OS analysis was event-driven and occurred 14 months after the MFS analysis <0.0001 Overall survival Deaths (%) 148 (15) 106 (19) Median, months (95% CI) NR (56.1, NR) NR (46.9, NR) Hazard Ratio (95% CI) 0.69 (0.53, 0.88) P-value P-value is based on a log-rank test stratified by PSADT (≤ 6 months vs. > 6 months) and use of osteoclast-targeted therapy (yes vs. no) 0.003 Figure 1: Kaplan-Meier Curve Metastasis Free Survival; Intent-To-Treat nmCRPC population (ARAMIS) Figure 2: Kaplan-Meier curves of Overall Survival; Intent-To-Treat nmCRPC population (ARAMIS) MFS results were consistent across patient subgroups for PSADT (≤ 6 months or > 6 months) or prior use of bone-targeting agents (yes or no). Treatment with NUBEQA resulted in a statistically significant delay in time to pain progression (HR = 0.65, 95% CI= 0.53, 0.79; p < 0.0001). Time to pain progression was defined as at least a 2-point worsening from baseline of the pain score on Brief Pain Inventory Short Form or initiation of opioids and reported in 28% of all patients on study. Treatment with NUBEQA resulted in a statistically significant delay in the initiation of cytotoxic chemotherapy (HR = 0.58, 95% CI = 0.44, 0.76; p < 0.0001). Figure 1 Figure 2 Metastatic Castration Sensitive Prostate Cancer (mCSPC) ARANOTE ARANOTE (NCT02799602) was a multicenter, double-blind, placebo-controlled study in 669 patients with mCSPC. Patients were randomized 2:1 to receive 600 mg NUBEQA orally twice daily (n=446) or matching placebo (n=223). Patients with both high- and low-volume mCSPC were eligible for the study. High-volume disease was defined as presence of visceral metastases, or 4 or more bone lesions, with at least 1 metastasis beyond the vertebral column and pelvic bones. Randomization was stratified by presence of visceral metastasis and use of prior local therapy at study entry. All patients received a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or had a bilateral orchiectomy. Treatment with NUBEQA or placebo continued until progressive disease, change of antineoplastic therapy, unacceptable toxicity, death, or withdrawal. The median age was 70 years (range 43-93) and 29% of patients were 75 years of age or older. The racial distribution was 56% White, 31% Asian, and 10% Black; while ethnicity included 24% Hispanic patients. Sixty-eight percent (68%) of patients had a Gleason score of 8 or higher at diagnosis. At study entry, ECOG PS of 0, 1, and 2 were 50%, 47%, and 3%, respectively. Seventy-three percent (73%) of patients had de novo disease and 22% had recurrent disease. Seventy-one percent (71%) of patients had high-volume disease, including 12% with visceral metastases, and 29% had low-volume disease. The median PSA level at baseline was 21 µg/L. One patient (0.2%) with a medical history of seizure was treated with NUBEQA in ARANOTE. The major efficacy outcome measure was radiographic progression-free survival (rPFS), defined as the time from randomization to radiological disease progression or death by central blinded review. Radiographic disease progression was defined by identification of 2 or more new bone lesions on a bone scan with confirmation (Prostate Cancer Working Group 3 criteria) and/or progression in soft tissue disease. Additional efficacy outcome measure was overall survival (OS). Treatment with NUBEQA resulted in a statistically significant improvement in rPFS compared to placebo. There was no statistically significant improvement in OS. Efficacy results for ARANOTE are shown in Table 8 and Figure 3. Table 8: Efficacy Results in Patients with mCSPC in ARANOTE Efficacy Endpoint NUBEQA (N=446) Placebo (N=223) NR: not reached NS: not statistically significant Radiographic Progression-Free Survival Patients with event, n (%) 128 (29) 94 (42) Median, months (95% CI) NR (NR, NR) 25 (19, NR) Hazard ratio (95% CI) Based on stratified Cox regression model 0.54 (0.41, 0.71) p-value Based on stratified log-rank test <0.0001 Overall Survival Patients with event, n (%) 115 (26) 70 (31) Median, months (95% CI) NR (NR, NR) NR (NR, NR) Hazard Ratio (95% CI) 0.78 (0.58, 1.05) p-value NS Figure 3: Kaplan-Meier Curves for Radiographic Progression-Free Survival; mCSPC population (ARANOTE) Figure 3 ARASENS ARASENS (NCT02799602) was a multicenter, double-blind, placebo-controlled clinical trial in 1306 patients with mCSPC. Patients were randomized 1:1 to receive 600 mg NUBEQA orally twice daily (n=651) or matching placebo (n=655), concomitantly with 75 mg/m 2 of docetaxel for 6 cycles. All patients received a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or had a bilateral orchiectomy. Treatment with NUBEQA or placebo continued until symptomatic progressive disease, change of antineoplastic therapy, or unacceptable toxicity. Patients with regional lymph node involvement only (M0) were excluded from the study. Patients were stratified by extent of disease (non–regional lymph nodes metastases only (M1a), bone metastases with or without lymph node metastases (M1b) or visceral metastases with or without lymph node metastases or with or without bone metastases (M1c)) and by alkaline phosphatase level (< or ≥ upper limit of normal) at study entry. The median age was 67 years (range 41–89) and 17% of patients were 75 years of age or older. The racial distribution included 52% White, 36% Asian, 4% Black, while ethnicity included 7% Hispanic patients. Seventy-eight percent (78%) of patients had a Gleason score of ≥8 at diagnosis. Seventy one percent (71%) of patients had an ECOG performance status score of 0 and 29% patients had an ECOG performance status score of 1. There were 86% of patients with de novo and 13% with recurrent disease. At initial diagnosis of metastatic disease, 3% had M1a, 83% had M1b and 14% had M1c disease; alkaline phosphatase was < ULN in 45% of patients and ≥ ULN in 55% of patients; median PSA level at baseline was 30 µg/L and 24 µg/L for NUBEQA vs placebo group, respectively. Four patients (0.6%) with a medical history of seizure were treated with NUBEQA with docetaxel in ARASENS. The major efficacy outcome measure was overall survival (OS). Time to pain progression was an additional efficacy outcome measure. Treatment with NUBEQA with docetaxel resulted in a statistically significant improvement in OS compared to placebo with docetaxel. OS results were consistent across stratified subgroups (extent of disease and alkaline phosphatase level). Efficacy results are shown in Table 9 and Figure 4. Table 9: Efficacy Results from the ARASENS study NUBEQA with docetaxel (N=651) Placebo with docetaxel (N=654) One patient in the placebo arm was excluded from all analyses due to the violation of Good Clinical Practices NR: not reached Overall survival Deaths (%) 229 (35) 304 (46) Median in months (95% CI) NR (NR, NR) 48.9 (44.4, NR) Hazard Ratio (95% CI) Hazard ratio < 1 favors NUBEQA 0.68 (0.57, 0.80) P-value P-value is one-sided, and based on a log-rank test stratified by extent of disease (non-regional lymph nodes metastases only or bone metastases with or without lymph node metastases or visceral metastases with or without lymph node metastases or with or without bone metastases) and Alkaline Phosphatase (ALP < ULN or ALP ≥ ULN) <0.0001 Figure 4: Kaplan-Meier curves of Overall Survival; mCSPC population (ARASENS) Treatment with NUBEQA with docetaxel resulted in a statistically significant delay in time to pain progression (HR = 0.79, 95% CI= 0.66, 0.95; 1-sided p value = 0.006). Time to pain progression was defined as the time from randomization to the time of pain progression. Pain progression is defined as: An increase of 2 or more points in the \"worst pain in 24 hours\" score (WPS) from nadir observed at 2 consecutive evaluations at least 4 weeks apart, or initiation of short- or long-acting opioid use for pain for at least 7 consecutive days, for asymptomatic patients (WPS=0) at baseline An increase of 2 or more points in the \"worst pain in 24 hours\" score (WPS) from nadir observed at 2 consecutive evaluations at least 4 weeks apart, and a WPS of 4 or greater, or initiation of short- or long-acting opioid use for pain for at least 7 consecutive days, for symptomatic patients (WPS ≥ 1) at baseline Patients with opioid use within 4 weeks before randomization were censored at randomization in this analysis (125 patients (19%) in the NUBEQA with docetaxel arm and 118 patients (18%) in the placebo with docetaxel arm). Figure 4"],"pharmacodynamics":["12.2 Pharmacodynamics PSA reduction was observed in CRPC patients receiving darolutamide doses of 100-900 mg twice a day, reaching a plateau of PSA reduction at the 600 mg twice daily dose. Twice daily dosing of 600 mg darolutamide in nmCRPC patients resulted in undetectable PSA levels in 24% of patients at 12 months compared to 0.4% of patients in the placebo arm. Twice daily dosing of 600 mg darolutamide in mCSPC patients resulted in undetectable PSA levels (<0.2 ng/mL) in 63% of patients compared to 19% of patients in the placebo arm. Twice daily dosing of 600 mg darolutamide in combination with docetaxel in mCSPC patients resulted in undetectable PSA levels in 60% of patients at 12 months compared to 26% of patients in the placebo with docetaxel arm. Cardiac Electrophysiology The effect of darolutamide (600 mg twice daily) on the QTc interval was evaluated in a subgroup of 500 patients in the ARAMIS study. No large mean increase in QTc (i.e., > 20 ms) was detected."],"pharmacokinetics":["12.3 Pharmacokinetics Following administration of 600 mg twice daily, darolutamide mean (%CV) steady-state peak plasma concentration (C max ) is 4.79 mg/L (30.9%) and area under the plasma concentration-time curve from time 0 to 12 hours (AUC 12h ) is 52.82 h∙µg/mL (33.9%). Steady-state is reached 2–5 days after repeated dosing with food, with an approximate 2-fold accumulation. The exposure (C max and AUC 12 ) of the darolutamide and the active metabolite ketodarolutamide increase in a nearly dose-proportional manner in the dose range of 100 to 700 mg (0.17 to 1.17 times the approved recommended dosage). No further increase in darolutamide exposure was observed at 900 mg twice daily (1.5 times the approved recommended dosage). Absorption Darolutamide C max is reached approximately 4 hours after administration of a single 600 mg oral dose. The absolute bioavailability is approximately 30% following oral administration of a NUBEQA tablet containing 300 mg darolutamide under fasted conditions. Food Effect Bioavailability of darolutamide increased by 2.0- to 2.5‑fold when administered with food. A similar increase of exposure was observed for the active metabolite ketodarolutamide. Distribution The apparent volume of distribution of darolutamide after intravenous administration is 119 L. Protein binding is 92% for darolutamide and 99.8% for the active metabolite, ketodarolutamide. Serum albumin is the main binding protein for darolutamide and ketodarolutamide. Elimination The effective half-life of darolutamide and ketodarolutamide is approximately 20 hours in patients. The clearance (%CV) of darolutamide following intravenous administration is 116 mL/min (39.7%). Metabolism Darolutamide is primarily metabolized by CYP3A4, as well as by UGT1A9 and UGT1A1. Ketodarolutamide total exposure in plasma is 1.7‑fold higher compared to darolutamide. Excretion After a single radiolabeled dose as an oral solution, a total of 63.4% of darolutamide‑related material is excreted in the urine (approximately 7% unchanged) and 32.4% (approximately 30% unchanged) in the feces. More than 95% of the dose was recovered within 7 days after administration. Specific Populations No clinically significant differences in the pharmacokinetics of darolutamide were observed based on age (41-95 years), race (White, Asian, Black or African American), mild to moderate renal impairment (eGFR 30–89 mL/min/1.73m 2 ), or mild hepatic impairment. In non-cancer subjects with severe renal impairment (eGFR 15–29 mL/min/1.73 m 2 ) not receiving dialysis or with moderate hepatic impairment (Child-Pugh Class B), NUBEQA exposure increased by about 2.5- and 1.9-fold, respectively, compared to healthy subjects. The effect of end-stage renal disease (eGFR <15 mL/min/1.73 m 2 ) or severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics has not been studied. Drug Interaction Studies Clinical Studies Combined P-gp and Strong CYP3A4 Inducers Concomitant use of rifampicin (a combined P-gp and strong CYP3A4 inducer) decreased mean darolutamide AUC 0-72 by 72% and C max by 52%. The decrease of darolutamide exposure by moderate CYP3A4 inducers is expected to be in the range of 36% – 58%. Combined P-gp and Strong CYP3A4 Inhibitors Itraconazole (a strong combined CYP3A4 and P-gp inhibitor) increased mean darolutamide AUC 0-72 by 1.7- and C max by 1.4-fold. CYP3A4 substrates Concomitant use of darolutamide decreased the mean AUC and C max of midazolam (CYP3A4 substrate) by 29% and 32%, respectively. No clinically relevant differences in the pharmacokinetics of midazolam were observed when used concomitantly with darolutamide. BCRP, OATP1B1 and OATP1B3 Substrates Concomitant use of darolutamide increased the mean AUC and C max of rosuvastatin (BCRP, OATP1B1 and OATP1B3 substrate) by approximately 5-fold. Docetaxel Administration of darolutamide in combination with docetaxel resulted in no clinically relevant changes in the pharmacokinetics of docetaxel in mCSPC patients. There were no clinically relevant changes in the pharmacokinetics of darolutamide, when used in combination with docetaxel . P-gp Substrates No clinically relevant differences in the pharmacokinetics of dabigatran (P-gp substrate) were observed when used concomitantly with darolutamide. In vitro , darolutamide did not inhibit the major CYP enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) or transporters (MRP2, BSEP, OATs, OCTs, MATEs, OATP2B1, and NTCP) at clinically relevant concentrations."],"adverse_reactions":["6 ADVERSE REACTIONS In nmCRPC and mCSPC : The most common adverse reactions (>10% with a ≥2% increase over placebo), including laboratory test abnormalities, are increased AST, decreased neutrophil count, increased bilirubin, fatigue, and increased ALT. ( 6.1 ) In mCSPC in combination with docetaxel : The most common adverse reactions (≥10% with a ≥2% increase over placebo) are constipation, rash, decreased appetite, hemorrhage, increased weight, and hypertension. The most common laboratory test abnormalities (≥30%) are anemia, hyperglycemia, decreased lymphocyte count, decreased neutrophil count, increased AST, increased ALT, and hypocalcemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or WWW.FDA.GOV/MEDWATCH. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled data in WARNINGS and PRECAUTIONS reflect two randomized clinical trials [ARAMIS, ARANOTE] in patients with nmCRPC (N = 954) and mCSPC (N = 445) treated with NUBEQA. In these trials, the median duration of treatment was 18.2 months (range 0.03 to 44.3) for patients who received NUBEQA [ see Clinical Studies (14) ]. In this pooled safety population, the most common adverse reactions (>10% with a ≥2% increase over placebo), including laboratory test abnormalities were increased AST, decreased neutrophil count, increased bilirubin, fatigue and increased ALT. The safety of NUBEQA in combination with docetaxel in mCSPC is based on data from 1302 patients of whom 652 received at least one dose of NUBEQA in the ARASENS study [ see Clinical Studies (14) ]. Non-Metastatic Castration Resistant Prostate Cancer ARAMIS The safety of NUBEQA in nmCRPC patients was evaluated in ARAMIS, a randomized (2:1), double-blind, placebo-controlled, multi-center clinical study [see Clinical Studies (14) ] . Patients received either NUBEQA at a dose of 600 mg, or a placebo, twice a day. All patients in the ARAMIS study received a concomitant gonadotropin-releasing hormone (GnRH) analog or had a bilateral orchiectomy. Among patients who received NUBEQA, the median duration of exposure was 14.8 months (range: 0 to 44.3 months). Serious adverse reactions occurred in 25% of patients receiving NUBEQA and in 20% of patients receiving placebo. Serious adverse reactions in ≥1% of patients who received NUBEQA included urinary retention, pneumonia and hematuria. Fatal adverse reactions occurred in 3.9% of patients receiving NUBEQA and 3.2% of patients receiving placebo. Fatal adverse reactions that occurred in ≥2 patients who received NUBEQA included death (0.4%), cardiac failure (0.3%), cardiac arrest (0.2%), general physical health deterioration (0.2%), and pulmonary embolism (0.2%). Permanent discontinuation of NUBEQA due to adverse reactions occurred in 9% of patients receiving NUBEQA. The most common adverse reactions requiring permanent discontinuation in patients who received NUBEQA included cardiac failure (0.4%), and death (0.4%). Dosage interruptions due to adverse reactions occurred in 13% of patients treated with NUBEQA. The most common adverse reactions requiring dosage interruption in patients who received NUBEQA included hypertension (0.6%), diarrhea (0.5%), and pneumonia (0.5%). Dosage reductions due to adverse reactions occurred in 6% of patients treated with NUBEQA. The most common adverse reactions requiring dosage reduction in patients treated with NUBEQA included fatigue (0.7%), hypertension (0.3%), and nausea (0.3%). The most common (>2% with a ≥2% increase compared to placebo) adverse reactions, including laboratory test abnormalities, were increased AST, decreased neutrophil count, fatigue, increased bilirubin, pain in extremity, and rash. Table 1 summarizes the adverse reactions in ARAMIS. Table 1: Adverse Reactions (>2% with a ≥2% increase compared to placebo) in Patients with nmCRPC in ARAMIS Adverse Reaction NUBEQA (N=954) Placebo (N=554) All Grades % Grades 3 or 4 % All Grades % Grade 3 or 4 % Fatigue Includes fatigue and asthenia 16 0.6 11 1.1 Pain in extremity 6 0 3 0.2 Rash Includes rash, eczema, rash maculo-papular, dermatitis, erythema multiforme, rash macular, rash papular, rash pustular, skin exfoliation 4 0.1 1.4 0 Clinically relevant adverse reactions occurring in 2% or more of patients treated with NUBEQA included ischemic heart disease (4%) and heart failure (2.1%). Table 2 summarizes the laboratory test abnormalities in ARAMIS. Table 2: Laboratory Test Abnormalities in ARAMIS Laboratory Abnormality NUBEQA (N=954) The denominator used to calculate the rate varied based on the number of patients with a baseline value and at least one post-treatment value. Placebo (N=554) All Grades % Grade 3 or 4 % All Grades % Grade 3 or 4 % AST increased 23 0.5 14 0.2 Neutrophil count decreased 20 4 9 0.6 Bilirubin increased 16 0.1 7 0 Metastatic Castration-Sensitive Prostate Cancer ARANOTE The safety of NUBEQA in mCSPC patients was evaluated in ARANOTE, a randomized (2:1), double-blind, placebo-controlled, multi-center clinical study [see Clinical Studies (14) ]. Patients received either NUBEQA at a dose of 600 mg, or a placebo, twice a day. All patients in the ARANOTE study received a concomitant gonadotropin-releasing hormone (GnRH) agonist or antagonist or had a bilateral orchiectomy. Among patients who received NUBEQA, the median duration of exposure was 24 months (range: 0.03 to 39 months). Serious adverse reactions occurred in 24% of patients receiving NUBEQA. Serious adverse reactions in ≥1% of patients who received NUBEQA included pneumonia (2%), urinary tract infection (1.8%), musculoskeletal pain (1.6%), hemorrhage (1.6%), arrhythmias (1.3%), and spinal cord compression (1.1%). Fatal adverse reactions occurred in 4.7% of patients receiving NUBEQA and those that occurred in ≥2 patients included sepsis (1.1%), craniocerebral injury (0.4%), and myocardial infarction (0.4%). Permanent discontinuation of NUBEQA due to adverse reactions occurred in 6% of patients treated in the NUBEQA arm. The most common adverse reactions which resulted in permanent discontinuation of NUBEQA were increased ALT, increased AST, craniocerebral injury, myocardial infarction, and rash (all with 0.4%). Dosage interruptions of NUBEQA due to adverse reactions occurred in 14% of patients treated in the NUBEQA arm. The most common adverse reactions requiring dosage interruption of NUBEQA were increased AST (1.6%), increased ALT (1.3%), and rash (1.3%). Dosage reductions of NUBEQA due to adverse reactions occurred in 3.6% of patients treated in the NUBEQA arm. The most common adverse reactions requiring dosage reduction of NUBEQA were increased AST (0.7%), rash (0.7%), increased ALT (0.4%), and hypertension (0.4%). Table 3 summarizes the adverse reactions in ARANOTE. Table 3: Adverse Reactions (≥10% with a ≥2% increase compared to placebo) in Patients with mCSPC in ARANOTE Adverse Reaction NUBEQA (N=445) Placebo (N=221) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Urinary Tract Infection 12 1.8 8 0.5 Clinically relevant adverse reactions in <10% of patients who received NUBEQA included arrhythmia (8.8%), pneumonia (3.6%), and myocardial infarction (0.7%). Table 4 summarizes the laboratory test abnormalities in ARANOTE. Table 4: Laboratory Test Abnormalities (≥15% with a ≥5% increase over placebo) in ARANOTE Laboratory Abnormality NUBEQA (N=445) The number of patients tested for a specific laboratory test parameter may be different. The incidence of each laboratory test abnormality was calculated accordingly. Placebo (N=221) All Grades Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 4 laboratory test values were limited to neutrophil count decreased. % Grade 3 or 4 % All Grades % Grade 3 or 4 % AST increased 32 2.8 25 0.5 ALT increased 28 2.1 23 0.5 Bilirubin increased 17 0.5 7 0 Neutrophil count decreased 16 1.2 9 0.5 ARASENS The safety of NUBEQA, in combination with docetaxel, in mCSPC patients was evaluated in ARASENS, a randomized (1:1), double-blind, placebo-controlled, multi-center clinical study [see Clinical Studies (14) ] . Patients were to receive either NUBEQA at a dose of 600 mg, or a placebo, twice a day in combination with docetaxel at a dose of 75 mg/m2 every 21 days for 6 cycles. All patients in the ARASENS study received a concomitant gonadotropin-releasing hormone (GnRH) agonist or antagonist or had a bilateral orchiectomy. Among patients who received NUBEQA, the median duration of exposure was 41 months (range: 0.1 to 56.5 months) vs. 16.7 months (range 0.3 to 55.8) with placebo. Eighty-eight percent and 86% of patients received the 6 planned cycles of docetaxel, in the NUBEQA with docetaxel arm and placebo with docetaxel arm, respectively. Serious adverse reactions occurred in 45% of patients receiving NUBEQA with docetaxel. Serious adverse reactions in ≥ 2% of patients who received NUBEQA with docetaxel included febrile neutropenia (6%), neutrophil count decreased (2.8%), musculoskeletal pain (2.6%) and pneumonia (2.6%). Fatal adverse reactions occurred in 4% of patients receiving NUBEQA with docetaxel. Fatal adverse reactions in ≥2 patients who received NUBEQA included COVID-19/COVID-19 pneumonia (0.8%), myocardial infarction (0.3%), and sudden death (0.3%). Permanent discontinuation of NUBEQA due to adverse reactions occurred in 14% of patients treated in the NUBEQA with docetaxel arm. The most common adverse reactions which resulted in permanent discontinuation of NUBEQA were rash (1.1%), musculoskeletal pain (0.9%), and increased aspartate aminotransferase (AST) (0.9%). Dosage interruptions of NUBEQA due to adverse reactions occurred in 23% of patients treated in the NUBEQA with docetaxel arm. The most common (>2%) adverse reactions requiring dosage interruption of NUBEQA were increased alanine aminotransferase (ALT) (3.2%), increased AST (3.1%) and febrile neutropenia (2.1%). Dosage reductions of NUBEQA due to adverse reactions occurred in 9% of patients treated in the NUBEQA with docetaxel arm. The most common (>2%) adverse reactions requiring dosage reduction of NUBEQA were increased ALT (2.8%) and increased AST (2.5%). The most common ( > 10% with a ≥2% increase over placebo with docetaxel) adverse reactions are constipation, rash, decreased appetite, hemorrhage, increased weight, and hypertension. The most common laboratory test abnormalities (≥30%) are anemia, hyperglycemia, decreased lymphocyte count, decreased neutrophil count, increased AST, increased ALT, and hypocalcemia. Table 5 summarizes the adverse reactions in ARASENS. Table 5: Adverse Reactions (≥10% with a ≥2% increase compared to placebo with docetaxel) in ARASENS Adverse Reaction NUBEQA with docetaxel (N=652) Placebo with docetaxel (N=650) All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Constipation 23 0.3 20 0.3 Rash Rash includes rash, rash maculo-papular, palmar-plantar erythrodysesthesia syndrome, eczema, dermatitis, skin exfoliation, dermatitis acneiform, drug eruption, rash pruritic, rash erythematous, erythema multiforme, rash macular, dermatitis exfoliative generalized, penile rash, dyshidrotic eczema, rash papular, dermatitis bullous, rash follicular, rash pustular, rash vesicular, toxic skin eruption 20 1.8 15 0.2 Decreased Appetite 19 0.2 13 0.6 Hemorrhage Hemorrhage includes hematuria, epistaxis, anal hemorrhage, hemorrhoidal hemorrhage, rectal hemorrhage, upper gastrointestinal hemorrhage, hemoptysis, hemorrhage urinary tract, hemorrhagic stroke, subarachnoid hemorrhage, lower gastrointestinal hemorrhage, cystitis hemorrhagic, gastrointestinal hemorrhage, hemorrhage subcutaneous, intra-abdominal hemorrhage, nail bed bleeding, subdural hemorrhage 18 1.4 13 1.4 Weight Increased 18 2.1 16 1.2 Hypertension Hypertension includes hypertension, blood pressure increased, hypertensive emergency and hypertensive crisis. 14 7 10 3.6 Clinically relevant adverse reactions in < 10% of patients who received NUBEQA with docetaxel included fractures (8%), ischemic heart disease (3.2%), seizures (0.6%), and drug-induced liver injury (0.3%). Table 6 summarizes laboratory test abnormalities in the ARASENS study. Table 6: Laboratory Test Abnormalities (≥30%) in ARASENS Laboratory Abnormality NUBEQA with docetaxel The denominator used to calculate the rate varied from 470 to 648 based on the number of patients with a baseline value and at least one post-treatment value. (N=652) Placebo with docetaxel (N=650) All Grades % Grade 3-4 % All Grades % Grade 3-4 % Anemia 72 6 71 7 Hyperglycemia 57 7 53 10 Lymphocyte count decreased 52 12 49 13 Neutrophil count decreased 49 33 44 31 AST increased ALT or AST increases to ≥5 × upper limit of normal (ULN) occurred in 5.3% of patients who received NUBEQA with docetaxel. ALT or AST increases to ≥20 × ULN occurred in 0.3% of patients who received NUBEQA with docetaxel. The median time to onset of any grade ALT or AST increases was 2.8 months (range: 0.03 to 46.9). 40 3.6 35 2.3 ALT increased 37 3.7 31 2.9 Hypocalcemia 31 2.8 28 1.9 Clinically relevant laboratory test abnormalities in < 30% of patients who received NUBEQA with docetaxel included blood bilirubin increased (all grades 20%, Grade 3-4 0.5%) compared to placebo with docetaxel (all grades 10%, grades 3-4 0.3%)."],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Combined P-gp and Strong or Moderate CYP3A Inducers : Avoid concomitant use. ( 7.1 ) Combined P-gp and Strong CYP3A Inhibitors : Monitor patients more frequently for NUBEQA adverse reactions. ( 7.1 ) BCRP Substrates : Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions and consider dose reduction of the BCRP substrate drug. ( 7.2 ) OATP1B1 and OATP1B3 Substrates : Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates. If used together, monitor patients more frequently for adverse reactions and consider dose reduction of these drugs. ( 7.2 ) 7.1 Effects of Other Drugs on NUBEQA Combined P-gp and Strong or Moderate CYP3A4 Inducer Concomitant use of NUBEQA with a combined P-gp and strong or moderate CYP3A4 inducer decreases darolutamide exposure which may decrease NUBEQA activity [see Clinical Pharmacology (12.3) ] . Avoid concomitant use of NUBEQA with combined P-gp and strong or moderate CYP3A4 inducers. Combined P-gp and Strong CYP3A4 Inhibitors Concomitant use of NUBEQA with a combined P-gp and strong CYP3A4 inhibitor increases darolutamide exposure [see Clinical Pharmacology (12.3) ] which may increase the risk of NUBEQA adverse reactions . Monitor patients more frequently for NUBEQA adverse reactions and modify NUBEQA dosage as needed [see Dosage and Administration (2.2) ] . 7.2 Effects of NUBEQA on Other Drugs Breast Cancer Resistance Protein (BCRP) and Organic Anion Transporting Polypeptides (OATP) 1B1 and 1B3 Substrates NUBEQA is an inhibitor of BCRP transporter. Concomitant use of NUBEQA increases the AUC and C max of BCRP substrates [see Clinical Pharmacology (12.3) ], which may increase the risk of BCRP substrate-related toxicities. Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions, and consider dose reduction of the BCRP substrate drug. NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters. Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates. Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA [see Clinical Pharmacology (12.3) ] , Review the prescribing information of the BCRP, OATP1B1 and OATP1B3 substrates when used concomitantly with NUBEQA."],"mechanism_of_action":["12.1 Mechanism of Action Darolutamide is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. A major metabolite, ketodarolutamide, exhibited similar in vitro activity to darolutamide. In addition, darolutamide functioned as a progesterone receptor (PR) antagonist in vitro (approximately 1% activity compared to AR). Darolutamide decreased prostate cancer cell proliferation in vitro and tumor volume in mouse xenograft models of prostate cancer."],"recent_major_changes":["Indications and Usage ( 1 ) 6/2025 Dosage and Administration ( 2.1 ) 6/2025 Warnings and Precautions ( 5.1 , 5.2 ) 6/2025"],"storage_and_handling":["Storage and Handling Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature] . Keep the bottle tightly closed after first opening."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Darolutamide is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. A major metabolite, ketodarolutamide, exhibited similar in vitro activity to darolutamide. In addition, darolutamide functioned as a progesterone receptor (PR) antagonist in vitro (approximately 1% activity compared to AR). Darolutamide decreased prostate cancer cell proliferation in vitro and tumor volume in mouse xenograft models of prostate cancer. 12.2 Pharmacodynamics PSA reduction was observed in CRPC patients receiving darolutamide doses of 100-900 mg twice a day, reaching a plateau of PSA reduction at the 600 mg twice daily dose. Twice daily dosing of 600 mg darolutamide in nmCRPC patients resulted in undetectable PSA levels in 24% of patients at 12 months compared to 0.4% of patients in the placebo arm. Twice daily dosing of 600 mg darolutamide in mCSPC patients resulted in undetectable PSA levels (<0.2 ng/mL) in 63% of patients compared to 19% of patients in the placebo arm. Twice daily dosing of 600 mg darolutamide in combination with docetaxel in mCSPC patients resulted in undetectable PSA levels in 60% of patients at 12 months compared to 26% of patients in the placebo with docetaxel arm. Cardiac Electrophysiology The effect of darolutamide (600 mg twice daily) on the QTc interval was evaluated in a subgroup of 500 patients in the ARAMIS study. No large mean increase in QTc (i.e., > 20 ms) was detected. 12.3 Pharmacokinetics Following administration of 600 mg twice daily, darolutamide mean (%CV) steady-state peak plasma concentration (C max ) is 4.79 mg/L (30.9%) and area under the plasma concentration-time curve from time 0 to 12 hours (AUC 12h ) is 52.82 h∙µg/mL (33.9%). Steady-state is reached 2–5 days after repeated dosing with food, with an approximate 2-fold accumulation. The exposure (C max and AUC 12 ) of the darolutamide and the active metabolite ketodarolutamide increase in a nearly dose-proportional manner in the dose range of 100 to 700 mg (0.17 to 1.17 times the approved recommended dosage). No further increase in darolutamide exposure was observed at 900 mg twice daily (1.5 times the approved recommended dosage). Absorption Darolutamide C max is reached approximately 4 hours after administration of a single 600 mg oral dose. The absolute bioavailability is approximately 30% following oral administration of a NUBEQA tablet containing 300 mg darolutamide under fasted conditions. Food Effect Bioavailability of darolutamide increased by 2.0- to 2.5‑fold when administered with food. A similar increase of exposure was observed for the active metabolite ketodarolutamide. Distribution The apparent volume of distribution of darolutamide after intravenous administration is 119 L. Protein binding is 92% for darolutamide and 99.8% for the active metabolite, ketodarolutamide. Serum albumin is the main binding protein for darolutamide and ketodarolutamide. Elimination The effective half-life of darolutamide and ketodarolutamide is approximately 20 hours in patients. The clearance (%CV) of darolutamide following intravenous administration is 116 mL/min (39.7%). Metabolism Darolutamide is primarily metabolized by CYP3A4, as well as by UGT1A9 and UGT1A1. Ketodarolutamide total exposure in plasma is 1.7‑fold higher compared to darolutamide. Excretion After a single radiolabeled dose as an oral solution, a total of 63.4% of darolutamide‑related material is excreted in the urine (approximately 7% unchanged) and 32.4% (approximately 30% unchanged) in the feces. More than 95% of the dose was recovered within 7 days after administration. Specific Populations No clinically significant differences in the pharmacokinetics of darolutamide were observed based on age (41-95 years), race (White, Asian, Black or African American), mild to moderate renal impairment (eGFR 30–89 mL/min/1.73m 2 ), or mild hepatic impairment. In non-cancer subjects with severe renal impairment (eGFR 15–29 mL/min/1.73 m 2 ) not receiving dialysis or with moderate hepatic impairment (Child-Pugh Class B), NUBEQA exposure increased by about 2.5- and 1.9-fold, respectively, compared to healthy subjects. The effect of end-stage renal disease (eGFR <15 mL/min/1.73 m 2 ) or severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics has not been studied. Drug Interaction Studies Clinical Studies Combined P-gp and Strong CYP3A4 Inducers Concomitant use of rifampicin (a combined P-gp and strong CYP3A4 inducer) decreased mean darolutamide AUC 0-72 by 72% and C max by 52%. The decrease of darolutamide exposure by moderate CYP3A4 inducers is expected to be in the range of 36% – 58%. Combined P-gp and Strong CYP3A4 Inhibitors Itraconazole (a strong combined CYP3A4 and P-gp inhibitor) increased mean darolutamide AUC 0-72 by 1.7- and C max by 1.4-fold. CYP3A4 substrates Concomitant use of darolutamide decreased the mean AUC and C max of midazolam (CYP3A4 substrate) by 29% and 32%, respectively. No clinically relevant differences in the pharmacokinetics of midazolam were observed when used concomitantly with darolutamide. BCRP, OATP1B1 and OATP1B3 Substrates Concomitant use of darolutamide increased the mean AUC and C max of rosuvastatin (BCRP, OATP1B1 and OATP1B3 substrate) by approximately 5-fold. Docetaxel Administration of darolutamide in combination with docetaxel resulted in no clinically relevant changes in the pharmacokinetics of docetaxel in mCSPC patients. There were no clinically relevant changes in the pharmacokinetics of darolutamide, when used in combination with docetaxel . P-gp Substrates No clinically relevant differences in the pharmacokinetics of dabigatran (P-gp substrate) were observed when used concomitantly with darolutamide. In vitro , darolutamide did not inhibit the major CYP enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) or transporters (MRP2, BSEP, OATs, OCTs, MATEs, OATP2B1, and NTCP) at clinically relevant concentrations."],"indications_and_usage":["1 INDICATIONS AND USAGE NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 ) NUBEQA is indicated for the treatment of adult patients with: non-metastatic castration resistant prostate cancer (nmCRPC) metastatic castration-sensitive prostate cancer (mCSPC) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Ischemic Heart Disease : Optimize management of cardiovascular risk factors. Monitor for signs and symptoms of coronary artery disease. Discontinue NUBEQA for Grade 3-4 events. ( 5.1 ) Seizure : Consider discontinuation of NUBEQA in patients who develop a seizure during treatment. ( 5.2 ) Embryo-Fetal Toxicity : NUBEQA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception. ( 5.3 , 8.1 , 8.3 ) 5.1 Ischemic Heart Disease Ischemic heart disease, including fatal cases, occurred in patients receiving NUBEQA. In a pooled analysis of ARAMIS and ARANOTE, ischemic heart disease occurred in 3.4% of patients receiving NUBEQA and 2.2% receiving placebo, including Grade 3-4 events in 1.4% and 0.3%, respectively. Ischemic events led to death in 0.4% of patients receiving NUBEQA and 0.4% receiving placebo. In ARASENS, ischemic heart disease occurred in 3.2% of patients receiving NUBEQA with docetaxel and 2% receiving placebo with docetaxel, including Grade 3-4 events in 1.3% and 1.1%, respectively. Ischemic events led to death in 0.3% of patients receiving NUBEQA with docetaxel and 0% receiving placebo with docetaxel. Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue NUBEQA for Grade 3-4 ischemic heart disease. 5.2 Seizure Seizure occurred in patients receiving NUBEQA. In a pooled analysis of ARAMIS and ARANOTE, Grade 1-3 seizure occurred in 0.2% of patients receiving NUBEQA. Seizure occurred from 261 to 665 days after initiation of NUBEQA. In ARASENS, seizure occurred in 0.8% of patients receiving NUBEQA with docetaxel, including two Grade 3 events. Seizure occurred from 38 to 1754 days after initiation of NUBEQA. It is unknown whether anti-epileptic medications will prevent seizures with NUBEQA. Advise patients of the risk of developing a seizure while receiving NUBEQA and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others. Consider discontinuation of NUBEQA in patients who develop a seizure during treatment. 5.3 Embryo-Fetal Toxicity The safety and efficacy of NUBEQA have not been established in females. Based on its mechanism of action, NUBEQA can cause fetal harm and loss of pregnancy when administered to a pregnant female [see Clinical Pharmacology (12.1) ] . Advise males with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose of NUBEQA [see Use in Specific Populations (8.1 , 8.3) ] ."],"clinical_studies_table":["
Table 7: Efficacy Results from the ARAMIS Study
NUBEQA (N=955)Placebo (N=554)
NR: not reached
Metastasis-free survivalLocoregional-only progression occurred in 6% of patients overall.
Distant Metastasis or Death (%)221 (23)216 (39)
Median, months (95% CI)Based on Kaplan-Meier estimates40.4 (34.3, NR)18.4 (15.5, 22.3)
Hazard Ratio (95% CI)Hazard ratio is based on a stratified Cox regression model. Hazard ratio < 1 favors NUBEQA.0.41 (0.34, 0.50)
P-valueThe pre-specified final OS analysis was event-driven and occurred 14 months after the MFS analysis<0.0001
Overall survival
Deaths (%)148 (15)106 (19)
Median, months (95% CI)NR (56.1, NR)NR (46.9, NR)
Hazard Ratio (95% CI)0.69 (0.53, 0.88)
P-valueP-value is based on a log-rank test stratified by PSADT (≤ 6 months vs. > 6 months) and use of osteoclast-targeted therapy (yes vs. no)0.003
","
Table 8: Efficacy Results in Patients with mCSPC in ARANOTE
Efficacy EndpointNUBEQA (N=446)Placebo (N=223)
NR: not reached
NS: not statistically significant
Radiographic Progression-Free Survival
Patients with event, n (%)128 (29)94 (42)
Median, months (95% CI)NR (NR, NR)25 (19, NR)
Hazard ratio (95% CI)Based on stratified Cox regression model0.54 (0.41, 0.71)
p-valueBased on stratified log-rank test<0.0001
Overall Survival
Patients with event, n (%)115 (26)70 (31)
Median, months (95% CI)NR (NR, NR)NR (NR, NR)
Hazard Ratio (95% CI)0.78 (0.58, 1.05)
p-valueNS
","
Table 9: Efficacy Results from the ARASENS study
NUBEQA with docetaxel (N=651)Placebo with docetaxel (N=654)One patient in the placebo arm was excluded from all analyses due to the violation of Good Clinical Practices
NR: not reached
Overall survival
Deaths (%)229 (35)304 (46)
Median in months (95% CI)NR (NR, NR)48.9 (44.4, NR)
Hazard Ratio (95% CI)Hazard ratio < 1 favors NUBEQA0.68 (0.57, 0.80)
P-valueP-value is one-sided, and based on a log-rank test stratified by extent of disease (non-regional lymph nodes metastases only or bone metastases with or without lymph node metastases or visceral metastases with or without lymph node metastases or with or without bone metastases) and Alkaline Phosphatase (ALP < ULN or ALP ≥ ULN)<0.0001
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Oral administration of darolutamide to male and female RasH2 transgenic mice for 26 weeks did not show carcinogenic potential at doses up to 1000 mg/kg/day. Darolutamide was clastogenic in an in vitro chromosome aberration assay in human peripheral blood lymphocytes. Darolutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in the in vivo combined bone marrow micronucleus assay and the Comet assay in the liver and duodenum of the rat. Fertility studies in animals have not been conducted with darolutamide. In repeat-dose toxicity studies in male rats (up to 26 weeks) and dogs (up to 39 weeks), tubular dilatation of testes, hypospermia, and atrophy of seminal vesicles, testes, prostate gland and epididymides were observed at doses ≥ 100 mg/kg/day in rats (0.6 times the human exposure based on AUC) and ≥ 50 mg/kg/day in dogs (approximately 1 times the human exposure based on AUC)."],"adverse_reactions_table":["
Table 1: Adverse Reactions (>2% with a ≥2% increase compared to placebo) in Patients with nmCRPC in ARAMIS
Adverse ReactionNUBEQA (N=954)Placebo (N=554)
All Grades %Grades 3 or 4 %All Grades %Grade 3 or 4 %
FatigueIncludes fatigue and asthenia160.6111.1
Pain in extremity6030.2
RashIncludes rash, eczema, rash maculo-papular, dermatitis, erythema multiforme, rash macular, rash papular, rash pustular, skin exfoliation40.11.40
","
Table 2: Laboratory Test Abnormalities in ARAMIS
Laboratory AbnormalityNUBEQA (N=954)The denominator used to calculate the rate varied based on the number of patients with a baseline value and at least one post-treatment value.Placebo (N=554)
All Grades %Grade 3 or 4 %All Grades %Grade 3 or 4 %
AST increased230.5140.2
Neutrophil count decreased 20490.6
Bilirubin increased160.170
","
Table 3: Adverse Reactions (≥10% with a ≥2% increase compared to placebo) in Patients with mCSPC in ARANOTE
Adverse ReactionNUBEQA (N=445)Placebo (N=221)
All Grades (%)Grade 3 or 4 (%)All Grades (%)Grade 3 or 4 (%)
Urinary Tract Infection121.880.5
","
Table 4: Laboratory Test Abnormalities (≥15% with a ≥5% increase over placebo) in ARANOTE
Laboratory AbnormalityNUBEQA (N=445)The number of patients tested for a specific laboratory test parameter may be different. The incidence of each laboratory test abnormality was calculated accordingly.Placebo (N=221)
All GradesCommon Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 4 laboratory test values were limited to neutrophil count decreased. %Grade 3 or 4 %All Grades %Grade 3 or 4 %
AST increased322.8250.5
ALT increased282.1230.5
Bilirubin increased170.570
Neutrophil count decreased161.290.5
","
Table 5: Adverse Reactions (≥10% with a ≥2% increase compared to placebo with docetaxel) in ARASENS
Adverse ReactionNUBEQA with docetaxel (N=652)Placebo with docetaxel (N=650)
All Grades %Grades 3 or 4 %All Grades %Grades 3 or 4 %
Constipation230.3200.3
RashRash includes rash, rash maculo-papular, palmar-plantar erythrodysesthesia syndrome, eczema, dermatitis, skin exfoliation, dermatitis acneiform, drug eruption, rash pruritic, rash erythematous, erythema multiforme, rash macular, dermatitis exfoliative generalized, penile rash, dyshidrotic eczema, rash papular, dermatitis bullous, rash follicular, rash pustular, rash vesicular, toxic skin eruption201.8150.2
Decreased Appetite190.2130.6
HemorrhageHemorrhage includes hematuria, epistaxis, anal hemorrhage, hemorrhoidal hemorrhage, rectal hemorrhage, upper gastrointestinal hemorrhage, hemoptysis, hemorrhage urinary tract, hemorrhagic stroke, subarachnoid hemorrhage, lower gastrointestinal hemorrhage, cystitis hemorrhagic, gastrointestinal hemorrhage, hemorrhage subcutaneous, intra-abdominal hemorrhage, nail bed bleeding, subdural hemorrhage181.4131.4
Weight Increased182.1161.2
HypertensionHypertension includes hypertension, blood pressure increased, hypertensive emergency and hypertensive crisis.147103.6
","
Table 6: Laboratory Test Abnormalities (≥30%) in ARASENS
Laboratory AbnormalityNUBEQA with docetaxelThe denominator used to calculate the rate varied from 470 to 648 based on the number of patients with a baseline value and at least one post-treatment value. (N=652)Placebo with docetaxel (N=650)
All Grades %Grade 3-4 %All Grades %Grade 3-4 %
Anemia726717
Hyperglycemia5775310
Lymphocyte count decreased52124913
Neutrophil count decreased49334431
AST increasedALT or AST increases to ≥5 × upper limit of normal (ULN) occurred in 5.3% of patients who received NUBEQA with docetaxel. ALT or AST increases to ≥20 × ULN occurred in 0.3% of patients who received NUBEQA with docetaxel. The median time to onset of any grade ALT or AST increases was 2.8 months (range: 0.03 to 46.9).403.6352.3
ALT increased373.7312.9
Hypocalcemia312.8281.9
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information) Ischemic Heart Disease Inform patients that NUBEQA has been associated with an increased risk of ischemic heart disease. Advise patients to seek immediate medical attention if any symptoms suggestive of an ischemic heart disease event occur [see Warnings and Precautions (5.1) ]. Seizure Inform patients that NUBEQA has been associated with an increased risk of seizure. Discuss conditions that may predispose to seizures and medications that may lower the seizure threshold. Advise patients of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Inform patients to contact their healthcare provider right away if they have loss of consciousness or seizure [see Warnings and Precautions (5.2) ]. Embryo-Fetal Toxicity Inform patients that NUBEQA can be harmful to a developing fetus and can cause loss of pregnancy [see Use in Specific Populations (8.1) ] . Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose of NUBEQA [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1 , 8.3) ]. Dosage and Administration Inform patients receiving concomitant gonadotropin-releasing hormone (GnRH) agonist or antagonist therapy that they need to maintain this treatment during the course of treatment with NUBEQA. Instruct patients to take their dose of two tablets (twice daily). NUBEQA should be taken with food. Each tablet should be swallowed whole. Inform patients that in the event of a missed daily dose of NUBEQA, to take any missed dose, as soon as they remember prior to the next scheduled dose, and not to take two doses together to make up for a missed dose [see Dosage and Administration (2.1) ]. Infertility Advise male patients that NUBEQA may impair fertility [see Use in Specific Populations (8.3) ]."],"spl_unclassified_section":["Manufactured by: Orion Corporation, Orion Pharma, FI-02101 Espoo, Finland Manufactured for: Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981 USA © 2019 Bayer HealthCare Pharmaceuticals Inc. For more information, call Bayer HealthCare Pharmaceuticals Inc. at Bayer at 1-888-842-2937 or go to www.NUBEQA-us.com"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended Dosage : NUBEQA 600 mg (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take NUBEQA with food. ( 2.1 ) For patients with mCSPC treated with NUBEQA in combination with docetaxel, administer the first cycle of docetaxel within 6 weeks after the start of NUBEQA treatment. ( 2.1 ) Patients should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had bilateral orchiectomy. ( 2.1 ) 2.1 Recommended Dosage The recommended dose of NUBEQA is 600 mg (two 300 mg tablets) taken orally, twice daily, with food [see Clinical Pharmacology (12.3) ]. Continue treatment until disease progression or unacceptable toxicity occurs. Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had a bilateral orchiectomy. When used in combination with docetaxel for mCSPC, administer the first of 6 cycles of docetaxel within 6 weeks after the start of NUBEQA treatment. Refer to docetaxel prescribing information for additional dosing information, including dosage modifications. Treatment with NUBEQA may be continued until disease progression or unacceptable toxicity, even if a cycle of docetaxel is delayed, interrupted, or discontinued [see Dosage and Administration (2.2) ] . Advise patients to swallow tablets whole with food, to take any missed dose as soon as they remember prior to the next scheduled dose, and not to take two doses together to make up for a missed dose. 2.2 Dosage Modification If a patient experiences a greater than or equal to Grade 3 or an intolerable adverse reaction, withhold NUBEQA or reduce dosage to 300 mg twice daily until symptoms improve. NUBEQA may be resumed at a dose of 600 mg twice daily, when adverse reaction returns to baseline [see Adverse Reactions (6.1) ]. Dosage reduction below 300 mg twice daily is not recommended. For patients who experience ischemic heart disease or seizure, additional dose modifications may be required [ see Warnings and Precautions (5.1 and 5.2) ]. 2.3 Recommended Dosage in Patients with Severe Renal Impairment For patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m 2 ) not receiving hemodialysis, the recommended dose of NUBEQA is 300 mg twice daily [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ] . 2.4 Recommended Dosage in Patients with Moderate Hepatic Impairment For patients with moderate hepatic impairment (Child-Pugh Class B), the recommended dose of NUBEQA is 300 mg twice daily [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ] ."],"spl_product_data_elements":["NUBEQA darolutamide DAROLUTAMIDE DAROLUTAMIDE ANHYDROUS DIBASIC CALCIUM PHOSPHATE CROSCARMELLOSE SODIUM LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE K30 POLYETHYLENE GLYCOL 3350 TITANIUM DIOXIDE to off white 300;Bayer"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets (300 mg): white to off-white oval film-coated tablets marked with \"300\" on one side and \"Bayer\" on the other. Tablets: 300 mg ( 3 )"],"recent_major_changes_table":["
Indications and Usage (1)6/2025
Dosage and Administration (2.1)6/2025
Warnings and Precautions (5.1, 5.2)6/2025
"],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 6/2025 PATIENT INFORMATION NUBEQA ® ( NOO-bə-kə) (darolutamide) tablets What is NUBEQA? NUBEQA is a prescription medicine used to treat adults with prostate cancer: that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone that has spread to other parts of the body and responds to a medical or surgical treatment that lowers testosterone that has spread to other parts of the body and responds to a medical or surgical treatment that lowers testosterone in combination with docetaxel. It is not known if NUBEQA is safe and effective in females or children. Before taking NUBEQA, tell your healthcare provider about all your medical conditions, including if you: have heart problems have high blood pressure have diabetes have high amounts of fat or cholesterol in your blood (dyslipidemia) have a history of seizures, brain injury, stroke, or brain tumors have kidney or liver problems are pregnant or plan to become pregnant. NUBEQA can cause harm to your unborn baby and loss of pregnancy (miscarriage). have a partner who may become pregnant. Males who have female partners who may become pregnant should use effective birth control (contraception) during treatment and for 1 week after the last dose of NUBEQA. Talk with your healthcare provider about birth control methods. are breastfeeding or plan to breastfeed. It is not known if NUBEQA passes into breast milk. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. NUBEQA may affect the way other medicines work and other medicines may affect how NUBEQA works. You should not start or stop any medicine before you talk with the healthcare provider that prescribed NUBEQA. Know the medicines you take. Keep a list of them with you to show to your healthcare provider and pharmacist when you get a new medicine. How should I take NUBEQA? Take NUBEQA exactly as your healthcare provider tells you. Your healthcare provider may change your dose, temporarily stop, or completely stop your treatment with NUBEQA if you have certain side effects. Take your prescribed dose of NUBEQA 2 times a day with food. Swallow NUBEQA tablets whole. If you are receiving gonadotropin-releasing hormone (GnRH) therapy, you should continue with this treatment during your treatment with NUBEQA unless you have had a surgery to lower the amount of testosterone in your body (surgical castration). If you miss a dose of NUBEQA, take your prescribed dose as soon as you remember before the next scheduled dose. Do not take 2 doses together to make up for a missed dose. If you take more NUBEQA than prescribed, call your healthcare provider right away. What are the possible side effects of NUBEQA? NUBEQA may cause serious side effects, including: Heart disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with NUBEQA. Your healthcare provider will monitor you for signs and symptoms of heart problems during your treatment with NUBEQA. Call your healthcare provider or get medical help right away if you get chest pain or discomfort at rest or with activity, or shortness of breath during your treatment with NUBEQA. Seizure. Treatment with NUBEQA may increase your risk of having a seizure. You should avoid activities where a sudden loss of consciousness could cause serious harm to yourself or others. Tell your healthcare provider right away if you have loss of consciousness or seizure during treatment with NUBEQA. The most common side effects of NUBEQA include: increase in liver function tests decreased white blood cells (neutropenia) feeling more tired than usual The most common side effects of NUBEQA in combination with docetaxel include : constipation rash decreased appetite bleeding weight gain high blood pressure decreased red blood cells (anemia) high blood sugar levels decreased white blood cells increase in liver function tests low blood calcium levels NUBEQA may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of NUBEQA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store NUBEQA? Store NUBEQA at room temperature between 68°F to 77°F (20°C to 25°C). Keep the bottle tightly closed after you first open it. Keep NUBEQA and all medicines out of the reach of children. General information about the safe and effective use of NUBEQA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use NUBEQA for a condition for which it was not prescribed. Do not give NUBEQA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about NUBEQA that is written for health professionals. What are the ingredients in NUBEQA? Active ingredient: darolutamide Inactive ingredients: calcium hydrogen phosphate, croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K 30, hypromellose 15 cP, macrogol 3350, and titanium dioxide. Manufactured by: Orion Corporation, Orion Pharma, FI-02101 Espoo, Finland Manufactured for: Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981 USA © 2019 Bayer HealthCare Pharmaceuticals Inc. For more information, call Bayer HealthCare Pharmaceuticals Inc. at Bayer at 1-888-842-2937 or go to www.NUBEQA-us.com"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Severe Renal Impairment (not on hemodialysis): Recommended dose is 300 mg twice daily. ( 8.6 ) Moderate Hepatic Impairment: Recommended dose is 300 mg twice daily. ( 8.7 ) 8.1 Pregnancy Risk Summary The safety and efficacy of NUBEQA have not been established in females. Based on its mechanism of action, NUBEQA can cause fetal harm and loss of pregnancy [see Clinical Pharmacology (12.1) ]. Animal embryo-fetal developmental toxicology studies were not conducted with darolutamide. There are no human data on the use of NUBEQA in pregnant females. 8.2 Lactation Risk Summary The safety and efficacy of NUBEQA have not been established in females. There are no data on the presence of darolutamide or its metabolites in human milk, the effect on the breastfed child, or the effect on milk production. 8.3 Females and Males of Reproductive Potential Contraception Males Based on the mechanism of action, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose of NUBEQA [see Use in Specific Populations (8.1) ]. Infertility Males Based on animal studies, NUBEQA may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use Safety and effectiveness of NUBEQA in pediatric patients have not been established. 8.5 Geriatric Use Of the 954 patients who received NUBEQA in ARAMIS, 88% of patients were 65 years and over, and 49% were 75 years and over. Of the 445 patients who received NUBEQA in ARANOTE, 74% of patients were 65 years and over, and 30% were 75 years and over. Of the 652 patients who received NUBEQA in ARASENS, 63% of patients were 65 years and over, and 16% were 75 years and over. No overall differences in safety or efficacy were observed between these patients and younger patients in both studies. 8.6 Renal Impairment Patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m 2 ) who are not receiving hemodialysis have a higher exposure to NUBEQA and reduction of the dose is recommended [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ]. No dose reduction is needed for patients with mild or moderate renal impairment (eGFR 30-89 mL/min/1.73 m 2 ) . The effect of end stage renal disease (eGFR ≤15 mL/min/1.73 m 2 ) on darolutamide pharmacokinetics is unknown. 8.7 Hepatic Impairment Patients with moderate hepatic impairment (Child-Pugh Class B) have a higher exposure to NUBEQA and reduction of the dose is recommended [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) ]. No dose reduction is needed for patients with mild hepatic impairment. The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown."],"spl_patient_package_insert_table":["
This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: 6/2025
PATIENT INFORMATION NUBEQA® (NOO-bə-kə) (darolutamide) tablets
What is NUBEQA? NUBEQA is a prescription medicine used to treat adults with prostate cancer: that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosteronethat has spread to other parts of the body and responds to a medical or surgical treatment that lowers testosteronethat has spread to other parts of the body and responds to a medical or surgical treatment that lowers testosterone in combination with docetaxel. It is not known if NUBEQA is safe and effective in females or children.
Before taking NUBEQA, tell your healthcare provider about all your medical conditions, including if you:have heart problemshave high blood pressurehave diabeteshave high amounts of fat or cholesterol in your blood (dyslipidemia)have a history of seizures, brain injury, stroke, or brain tumorshave kidney or liver problemsare pregnant or plan to become pregnant. NUBEQA can cause harm to your unborn baby and loss of pregnancy (miscarriage).have a partner who may become pregnant. Males who have female partners who may become pregnant should use effective birth control (contraception) during treatment and for 1 week after the last dose of NUBEQA. Talk with your healthcare provider about birth control methods.are breastfeeding or plan to breastfeed. It is not known if NUBEQA passes into breast milk.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NUBEQA may affect the way other medicines work and other medicines may affect how NUBEQA works. You should not start or stop any medicine before you talk with the healthcare provider that prescribed NUBEQA. Know the medicines you take. Keep a list of them with you to show to your healthcare provider and pharmacist when you get a new medicine.
How should I take NUBEQA?Take NUBEQA exactly as your healthcare provider tells you.Your healthcare provider may change your dose, temporarily stop, or completely stop your treatment with NUBEQA if you have certain side effects.Take your prescribed dose of NUBEQA 2 times a day with food.Swallow NUBEQA tablets whole.If you are receiving gonadotropin-releasing hormone (GnRH) therapy, you should continue with this treatment during your treatment with NUBEQA unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).If you miss a dose of NUBEQA, take your prescribed dose as soon as you remember before the next scheduled dose. Do not take 2 doses together to make up for a missed dose.If you take more NUBEQA than prescribed, call your healthcare provider right away.
What are the possible side effects of NUBEQA? NUBEQA may cause serious side effects, including:Heart disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with NUBEQA. Your healthcare provider will monitor you for signs and symptoms of heart problems during your treatment with NUBEQA. Call your healthcare provider or get medical help right away if you get chest pain or discomfort at rest or with activity, or shortness of breath during your treatment with NUBEQA.Seizure. Treatment with NUBEQA may increase your risk of having a seizure. You should avoid activities where a sudden loss of consciousness could cause serious harm to yourself or others. Tell your healthcare provider right away if you have loss of consciousness or seizure during treatment with NUBEQA.
The most common side effects of NUBEQA include:
increase in liver function testsdecreased white blood cells (neutropenia)feeling more tired than usual
The most common side effects of NUBEQA in combination with docetaxel include:
constipationrashdecreased appetitebleedingweight gainhigh blood pressuredecreased red blood cells (anemia)high blood sugar levels decreased white blood cells increase in liver function testslow blood calcium levels
NUBEQA may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of NUBEQA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store NUBEQA?Store NUBEQA at room temperature between 68°F to 77°F (20°C to 25°C).Keep the bottle tightly closed after you first open it.Keep NUBEQA and all medicines out of the reach of children.
General information about the safe and effective use of NUBEQA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use NUBEQA for a condition for which it was not prescribed. Do not give NUBEQA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about NUBEQA that is written for health professionals.
What are the ingredients in NUBEQA? Active ingredient: darolutamide Inactive ingredients: calcium hydrogen phosphate, croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K 30, hypromellose 15 cP, macrogol 3350, and titanium dioxide. Manufactured by: Orion Corporation, Orion Pharma, FI-02101 Espoo, Finland Manufactured for: Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981 USA © 2019 Bayer HealthCare Pharmaceuticals Inc. For more information, call Bayer HealthCare Pharmaceuticals Inc. at Bayer at 1-888-842-2937 or go to www.NUBEQA-us.com
"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL 50419-395-01 Rx Only NUBEQA (darolutamide) tablets 300 mg 120 film-coated tablets NUBEQA 300 mg label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Oral administration of darolutamide to male and female RasH2 transgenic mice for 26 weeks did not show carcinogenic potential at doses up to 1000 mg/kg/day. Darolutamide was clastogenic in an in vitro chromosome aberration assay in human peripheral blood lymphocytes. Darolutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in the in vivo combined bone marrow micronucleus assay and the Comet assay in the liver and duodenum of the rat. Fertility studies in animals have not been conducted with darolutamide. In repeat-dose toxicity studies in male rats (up to 26 weeks) and dogs (up to 39 weeks), tubular dilatation of testes, hypospermia, and atrophy of seminal vesicles, testes, prostate gland and epididymides were observed at doses ≥ 100 mg/kg/day in rats (0.6 times the human exposure based on AUC) and ≥ 50 mg/kg/day in dogs (approximately 1 times the human exposure based on AUC)."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Androgen receptor","category":"target"},{"label":"AR","category":"gene"},{"label":"PGR","category":"gene"},{"label":"L02BB06","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Hormone refractory prostate cancer","category":"indication"},{"label":"Metastatic prostate cancer","category":"indication"},{"label":"Bayer Healthcare","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":220.533,"date":"","count":45,"signal":"Prostatic specific antigen increased","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=221)"},{"llr":52.399,"date":"","count":17,"signal":"Metastases to bone","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=52)"}],"commonSideEffects":[{"effect":"Fatigue","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Pain in extremity","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Rash","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Ischemic heart disease","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Heart failure","drugRate":"2.1%","severity":"serious","_validated":true},{"effect":"AST increased","drugRate":"2.3%","severity":"common","_validated":true},{"effect":"Bilirubin increased","drugRate":"1.6%","severity":"common","_validated":true},{"effect":"Neutrophil count decreased","drugRate":"1.9%","severity":"common","_validated":true}],"specialPopulations":{"Pregnancy":"The safety and efficacy of NUBEQA have not been established in females. Based on its mechanism of action, NUBEQA can cause fetal harm and loss of pregnancy. Animal embryo-fetal developmental toxicology studies were not conducted with darolutamide. There are no human data on the use of NUBEQA in pregnant females.","Geriatric use":"Of the 954 patients who received NUBEQA in ARAMIS, 88% of patients were 65 years and over, and 49% were 75 years and over. No overall differences in safety or efficacy were observed between these patients and younger patients.","Paediatric use":"Safety and effectiveness of NUBEQA in pediatric patients have not been established.","Renal impairment":"Severe Renal Impairment (not on hemodialysis): Recommended dose is 300 mg twice daily.","Hepatic impairment":"Moderate Hepatic Impairment: Recommended dose is 300 mg twice daily."}},"trials":[],"aliases":[],"company":"Bayer","patents":[{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Jan 28, 2036","useCode":"U-4210","territory":"US","drugProduct":true,"patentNumber":"10835515","drugSubstance":false},{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Mar 25, 2033","useCode":"U-4208","territory":"US","drugProduct":true,"patentNumber":"8975254","drugSubstance":true},{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Oct 27, 2030","useCode":"U-4209","territory":"US","drugProduct":true,"patentNumber":"9657003","drugSubstance":true},{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Jun 17, 2042","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12329742","drugSubstance":false},{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Jan 28, 2036","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10010530","drugSubstance":true},{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Oct 27, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11046713","drugSubstance":true},{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Jan 28, 2036","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10383853","drugSubstance":true},{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Feb 27, 2038","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11168058","drugSubstance":true},{"applNo":"N212099","source":"FDA Orange Book","status":"Active","expires":"Oct 27, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10711013","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=darolutamide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:43:41.812197+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:43:41.812098+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:43:48.793854+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:43:41.937611+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:43:37.640014+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=darolutamide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:43:49.492789+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:35.968626+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:44:51.661571+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:35.968655+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Darolutamide is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. A major metabolite, ketodarolutamide, exhibited similar in vitro activity to darolutamide. In addition, darolutamide functioned as a progesterone receptor (PR) antagonist in vitro (approximately 1% activity compared to AR). Darolutamide decreased prostate cancer cell proliferation in vitro and tumor volume in ","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:44:27.298274+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:50.574969+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297185/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:50.221001+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA212099","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:35.968659+00:00"}},"allNames":"nubeqa","offLabel":[],"synonyms":["darolutamide","nubeqa","BAY 1841788","ODM-201"],"timeline":[{"date":"2019-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BAYER HEALTHCARE PHARMACEUTICALS INC to Bayer Healthcare"},{"date":"2019-07-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bayer Healthcare Pharmaceuticals Inc)"},{"date":"2020-01-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Bayer Yakuhin, Ltd)"},{"date":"2020-03-27","type":"positive","source":"DrugCentral","milestone":"EMA approval (Bayer AG)"},{"date":"2028-06-03","type":"negative","source":"FDA Orange Book","milestone":"I-971 exclusivity expires"},{"date":"2030-10-27","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 9657003 expires"},{"date":"2033-03-25","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8975254 expires"},{"date":"2036-01-28","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 10010530 expires"},{"date":"2038-02-27","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 11168058 expires"}],"aiSummary":"Nubeqa (darolutamide) is a small molecule modality developed by Bayer Healthcare Pharmaceuticals Inc, targeting the androgen receptor. It is FDA-approved for the treatment of hormone refractory and metastatic prostate cancer. Nubeqa is a patented medication with no generic manufacturers available. Key safety considerations include potential side effects such as fatigue, nausea, and increased risk of fractures. As a relatively new medication, its long-term safety profile is still being evaluated.","approvals":[{"date":"2019-07-30","orphan":false,"company":"BAYER HEALTHCARE PHARMACEUTICALS INC","regulator":"FDA"},{"date":"2020-01-23","orphan":false,"company":"Bayer Yakuhin, Ltd","regulator":"PMDA"},{"date":"2020-03-27","orphan":false,"company":"Bayer AG","regulator":"EMA"}],"brandName":"Nubeqa","ecosystem":[{"indication":"Hormone refractory prostate cancer","otherDrugs":[{"name":"niraparib","slug":"niraparib","company":"Tesaro Inc"},{"name":"olaparib","slug":"olaparib","company":"Astrazeneca Pharms"}],"globalPrevalence":null},{"indication":"Metastatic prostate cancer","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"androgen receptor (AR)","novelty":"Follow-on","targets":[{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"},{"gene":"PGR","source":"DrugCentral","target":"Progesterone receptor","protein":"Progesterone receptor"}],"modality":"Small molecule","explanation":"Darolutamide works by blocking the androgen receptor, which prevents testosterone from binding and activating the receptor. This inhibition stops the receptor from moving into the nucleus and activating genes that promote cancer cell growth, leading to reduced tumor size in prostate cancer models.","oneSentence":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size.","technicalDetail":"Darolutamide competitively inhibits androgen binding to the androgen receptor (AR), preventing AR nuclear translocation and AR-mediated transcription. It also functions as a weak progesterone receptor (PR) antagonist in vitro. The major metabolite, ketodarolutamide, exhibits similar in vitro activity to darolutamide."},"commercial":{"launchDate":"2019","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2019-07-30, BAYER HEALTHCARE PHARMACEUTICALS INC)","annualRevenue":1600,"revenueSource":"Bayer AR 2024","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5334","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=darolutamide","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=darolutamide","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:29:54.772087","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:44:51.791326+00:00","fieldsConflicting":4,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"flutamide","drugSlug":"flutamide","fdaApproval":"1989-01-27","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nilutamide","drugSlug":"nilutamide","fdaApproval":"1996-09-19","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bicalutamide","drugSlug":"bicalutamide","fdaApproval":"1995-10-04","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"enzalutamide","drugSlug":"enzalutamide","fdaApproval":"2012-08-31","patentExpiry":"Sep 11, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"apalutamide","drugSlug":"apalutamide","fdaApproval":"2018-02-14","patentExpiry":"Sep 23, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"I-971","date":"Jun 3, 2028"}],"genericName":"darolutamide","indications":{"approved":[{"id":"darolutamide-non-metastatic-castration-resi","name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC)","diagnosticRequired":null,"brandNameForIndication":"Nubeqa"},{"id":"darolutamide-metastatic-castration-sensitiv","name":"Metastatic castration-sensitive prostate cancer (mCSPC)","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients with metastatic castration-sensitive prostate cancer (mCSPC)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients with metastatic castration-sensitive prostate cancer (mCSPC)","diagnosticRequired":null,"brandNameForIndication":"Nubeqa"},{"id":"darolutamide-metastatic-castration-sensitiv","name":"Metastatic castration-sensitive prostate cancer (mCSPC) with docetaxel","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients with metastatic castration-sensitive prostate cancer (mCSPC)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients with metastatic castration-sensitive prostate cancer (mCSPC)","diagnosticRequired":null,"brandNameForIndication":"Nubeqa"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bayer Healthcare","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"flutamide","brandName":"flutamide","genericName":"flutamide","approvalYear":"1989","relationship":"same-class"},{"drugId":"nilutamide","brandName":"nilutamide","genericName":"nilutamide","approvalYear":"1996","relationship":"same-class"},{"drugId":"bicalutamide","brandName":"bicalutamide","genericName":"bicalutamide","approvalYear":"1995","relationship":"same-class"},{"drugId":"enzalutamide","brandName":"enzalutamide","genericName":"enzalutamide","approvalYear":"2012","relationship":"same-class"},{"drugId":"apalutamide","brandName":"apalutamide","genericName":"apalutamide","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06592924","phase":"PHASE3","title":"Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2025-05-28","conditions":["Prostate Cancer (Adenocarcinoma)"],"enrollment":830,"completionDate":"2031-04-15"},{"nctId":"NCT05826509","phase":"PHASE2","title":"SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2023-08-10","conditions":["Prostate Cancer"],"enrollment":240,"completionDate":"2031-02"},{"nctId":"NCT07103018","phase":"PHASE1","title":"A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)","status":"RECRUITING","sponsor":"K36 Therapeutics, Inc.","startDate":"2025-11-21","conditions":["Metastatic Castration-resistant Prostate Cancer","Metastatic Castration-Resistant Prostate Cancer Patients","Metastatic Castration-resistant Prostate Cancer, mCRPC","mCRPC","mCRPC (Metastatic Castration-resistant Prostate Cancer)"],"enrollment":144,"completionDate":"2028-09"},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":["Prostate Carcinoma"],"enrollment":27,"completionDate":"2028-05-31"},{"nctId":"NCT06661122","phase":"","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-11-18","conditions":["Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","Low-volume Metastasis"],"enrollment":100,"completionDate":"2031-08-31"},{"nctId":"NCT04122976","phase":"","title":"A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-01-30","conditions":["Prostate Cancer"],"enrollment":805,"completionDate":"2026-10-07"},{"nctId":"NCT06169124","phase":"PHASE2","title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-08","conditions":["Adult Ovarian Granulosa Cell Tumor"],"enrollment":37,"completionDate":"2027-05-31"},{"nctId":"NCT06282588","phase":"PHASE2,PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":["Prostate Cancer"],"enrollment":493,"completionDate":"2030-12-31"},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":["Prostate Cancer","High-risk Prostate Cancer"],"enrollment":40,"completionDate":"2031-05-02"},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":["Prostate Cancer"],"enrollment":1247,"completionDate":"2025-03-14"},{"nctId":"NCT05348876","phase":"PHASE4","title":"A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-08-03","conditions":["Non-metastatic Castration-resistant Prostate Cancer"],"enrollment":50,"completionDate":"2027-04-29"},{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":["Metastatic Hormone-Sensitive Prostate Cancer","Prostate Cancer"],"enrollment":168,"completionDate":"2025-12-03"},{"nctId":"NCT07476677","phase":"PHASE2","title":"Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-04-01","conditions":["Prostate Cancer"],"enrollment":60,"completionDate":"2028-03-31"},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":["Biochemically Recurrent Prostate Cancer"],"enrollment":985,"completionDate":"2030-03-29"},{"nctId":"NCT06173362","phase":"PHASE2","title":"Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-11-09","conditions":["Advanced Prostate Adenocarcinoma","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8"],"enrollment":75,"completionDate":"2027-05"},{"nctId":"NCT06334120","phase":"","title":"An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-09-25","conditions":["Non-metastatic Castration-resistant Prostate Cancer","Metastatic Hormone-sensitive Prostate Cancer"],"enrollment":600,"completionDate":"2028-06-30"},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":60,"completionDate":"2034-06-01"},{"nctId":"NCT05526248","phase":"PHASE2","title":"A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-12-19","conditions":["Biochemically Recurrent Prostate Cancer"],"enrollment":28,"completionDate":"2024-12-04"},{"nctId":"NCT07182279","phase":"PHASE1,PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":["Prostate Cancer (Adenocarcinoma)"],"enrollment":29,"completionDate":"2026-11-14"},{"nctId":"NCT06463457","phase":"PHASE2","title":"Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atish Choudhury, MD","startDate":"2024-12-13","conditions":["Prostate Cancer","Advanced Prostate Cancer","Hormone Sensitive Prostate Cancer"],"enrollment":33,"completionDate":"2028-11-30"},{"nctId":"NCT07450599","phase":"PHASE2","title":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-04-15","conditions":["High-Risk Localized Prostate Cancer"],"enrollment":250,"completionDate":"2030-10-15"},{"nctId":"NCT05999968","phase":"PHASE1","title":"Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-12","conditions":["Prostatic Neoplasms"],"enrollment":10,"completionDate":"2026-01-21"},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":["Prostatic Neoplasm"],"enrollment":49,"completionDate":"2026-12-23"},{"nctId":"NCT07190300","phase":"PHASE1,PHASE2","title":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-13","conditions":["Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":155,"completionDate":"2032-06-04"},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":["Metastatic Prostate Cancer","Non-metastatic Prostate Cancer","Prostate Cancer"],"enrollment":9,"completionDate":"2026-06-01"},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":["Prostatic Neoplasms"],"enrollment":669,"completionDate":"2026-01-23"},{"nctId":"NCT04104893","phase":"PHASE2","title":"A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-02-20","conditions":["Metastatic Castration Resistant Prostate Cancer"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT05997615","phase":"PHASE1","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer","status":"RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2023-08-10","conditions":["Hormone-refractory Prostate Cancer"],"enrollment":390,"completionDate":"2027-09-29"},{"nctId":"NCT05938270","phase":"PHASE1","title":"A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-21","conditions":["Prostate Cancer"],"enrollment":120,"completionDate":"2026-08-17"},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"enrollment":7,"completionDate":"2029-04-09"},{"nctId":"NCT06724159","phase":"","title":"Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.","status":"RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2024-12-13","conditions":["Genitourinary Cancers"],"enrollment":500,"completionDate":"2027-12"},{"nctId":"NCT07395804","phase":"","title":"How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-28","conditions":["Metastatic Hormone-sensitive Prostate Cancer (mHSPC)"],"enrollment":500,"completionDate":"2031-02-28"},{"nctId":"NCT05647564","phase":"NA","title":"PET/CT Characterization of Treatment Resistance","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-06","conditions":["Prostate Cancer"],"enrollment":25,"completionDate":"2026-09-01"},{"nctId":"NCT05818683","phase":"PHASE1","title":"A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-26","conditions":["Metastatic Castration-resistant Prostate Neoplasms","Metastatic Hormone-sensitive Prostate Cancer"],"enrollment":277,"completionDate":"2027-09-01"},{"nctId":"NCT07140900","phase":"PHASE1","title":"Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-10-07","conditions":["Metastatic Hormone-sensitive Prostate Cancer (mHSPC)"],"enrollment":60,"completionDate":"2030-03-30"},{"nctId":"NCT05683964","phase":"EARLY_PHASE1","title":"Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-01-19","conditions":["Prostate Adenocarcinoma","Prostate Cancer","Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":9,"completionDate":"2026-09-01"},{"nctId":"NCT04558866","phase":"PHASE2","title":"Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2021-06-09","conditions":["Prostate Cancer"],"enrollment":51,"completionDate":"2026-06"},{"nctId":"NCT07406282","phase":"","title":"A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-07-22","conditions":["Prostatic Neoplasms","Metastatic Hormone-Sensitive Prostate Cancer"],"enrollment":1400,"completionDate":"2026-02-28"},{"nctId":"NCT06627530","phase":"PHASE4","title":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2025-02-17","conditions":["Prostate Cancer"],"enrollment":144,"completionDate":"2026-09"},{"nctId":"NCT05059236","phase":"PHASE2","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-11-04","conditions":["Metastatic Hormone-sensitive Prostate Cancer"],"enrollment":223,"completionDate":"2026-06-05"},{"nctId":"NCT06631521","phase":"PHASE1","title":"Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"AdventHealth","startDate":"2024-10-22","conditions":["Prostate CA","Prostate Cancer (Adenocarcinoma)","Prostate Cancer Surgery"],"enrollment":30,"completionDate":"2026-06"},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":["mHSPC","mHNPC","Prostate Cancer Adenocarcinoma"],"enrollment":40,"completionDate":"2027-06"},{"nctId":"NCT04729114","phase":"PHASE1","title":"A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-06-14","conditions":["Prostate Cancer","Metastatic Castration Resistant Prostate Cancer","Metastatic Castration-sensitive Prostate Cancer"],"enrollment":174,"completionDate":"2029-05-31"},{"nctId":"NCT07244341","phase":"PHASE1","title":"A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-12-03","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":60,"completionDate":"2029-11-30"},{"nctId":"NCT04946370","phase":"PHASE1,PHASE2","title":"Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-08-12","conditions":["Prostate Cancer"],"enrollment":37,"completionDate":"2029-12"},{"nctId":"NCT07344779","phase":"","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-17","conditions":["Metastatic Hormone-Sensitive Prostate Cancer"],"enrollment":1600,"completionDate":"2030-06-30"},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":["Metastatic Castration Sensitive Prostate Cancer"],"enrollment":25,"completionDate":"2028-11"},{"nctId":"NCT06120491","phase":"PHASE3","title":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-21","conditions":["Metastatic Castration-Sensitive Prostate Cancer"],"enrollment":1800,"completionDate":"2031-04-30"},{"nctId":"NCT05519449","phase":"PHASE1","title":"Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)","status":"RECRUITING","sponsor":"Janux Therapeutics","startDate":"2022-09-15","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Castration Resistant Prostatic Cancer"],"enrollment":272,"completionDate":"2028-12"},{"nctId":"NCT06010914","phase":"","title":"A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-10-09","conditions":["Metastatic Hormone-sensitive Prostate Cancer (mHSPC)"],"enrollment":100,"completionDate":"2027-01-31"},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":["Prostate Adenocarcinoma"],"enrollment":2050,"completionDate":"2026-11-11"},{"nctId":"NCT06660862","phase":"PHASE4","title":"Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-11","conditions":["Prostate Cancer"],"enrollment":80,"completionDate":"2029-11"},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":["Recurrent Castration-Sensitive Prostate Carcinoma","Recurrent Prostate Cancer","Castration-resistant Prostate Cancer","Biochemically Recurrent Prostate Carcinoma"],"enrollment":532,"completionDate":"2029-05-31"},{"nctId":"NCT07282197","phase":"PHASE2","title":"Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2026-01","conditions":["Prostate Cancer"],"enrollment":40,"completionDate":"2029-06"},{"nctId":"NCT04025372","phase":"PHASE2","title":"INTREPId (INTermediate Risk Erection PreservatIon Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2020-06-01","conditions":["Prostate Cancer"],"enrollment":234,"completionDate":"2028-03-01"},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":["Metastatic Prostate Cancer","Prostate Cancer (Adenocarcinoma)","Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":112,"completionDate":"2027-12-30"},{"nctId":"NCT05367440","phase":"PHASE1,PHASE2","title":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-02","conditions":["Metastatic Prostate Cancer"],"enrollment":174,"completionDate":"2031-04-11"},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":["Metastatic Hormone-sensitive Prostate Cancer"],"enrollment":1306,"completionDate":"2023-04-11"},{"nctId":"NCT06594926","phase":"PHASE2","title":"Working Out M0 Bipolar Androgen Therapy","status":"RECRUITING","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2024-08-14","conditions":["Prostate Cancer"],"enrollment":69,"completionDate":"2028-12-31"},{"nctId":"NCT07181122","phase":"","title":"Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Ankara Etlik City Hospital","startDate":"2025-10-22","conditions":["Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":102,"completionDate":"2026-09-15"},{"nctId":"NCT05669664","phase":"PHASE2","title":"Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-20","conditions":["Locally Advanced Salivary Gland Carcinoma","Metastatic Salivary Gland Carcinoma","Recurrent Salivary Gland Carcinoma","Unresectable Salivary Gland Carcinoma"],"enrollment":21,"completionDate":"2027-04-11"},{"nctId":"NCT04464226","phase":"PHASE3","title":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","status":"RECRUITING","sponsor":"Bayer","startDate":"2020-10-20","conditions":["Cancer"],"enrollment":402,"completionDate":"2028-06-26"},{"nctId":"NCT04335682","phase":"PHASE2","title":"Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-08-17","conditions":["Metastatic Prostate Cancer","Prostate Cancer Metastatic","Prostate Cancer","Castrate Resistant Prostate Cancer","Hormone Sensitive Prostate Cancer","Non-metastatic Prostate Cancer"],"enrollment":111,"completionDate":"2026-08"},{"nctId":"NCT07223372","phase":"","title":"An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2025-11-07","conditions":["Metastatic Hormonesensitive Prostate Cancer (mHSPC)"],"enrollment":1000,"completionDate":"2026-11-30"},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Triple-Negative Breast Carcinoma"],"enrollment":51,"completionDate":"2033-10"},{"nctId":"NCT05346848","phase":"PHASE2","title":"Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2023-02-24","conditions":["Prostate Cancer"],"enrollment":62,"completionDate":"2030-02"},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":["Prostate Cancer Metastatic"],"enrollment":3360,"completionDate":"2032-03"},{"nctId":"NCT05974774","phase":"PHASE3","title":"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-05-23","conditions":["Prostate Cancer"],"enrollment":1600,"completionDate":"2039-06-01"},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":["Prostate Cancer"],"enrollment":61,"completionDate":"2036-12"},{"nctId":"NCT07172685","phase":"NA","title":"Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-30","conditions":["Prostate Cancer"],"enrollment":116,"completionDate":"2027-06-30"},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":["Salivary Gland Carcinoma","Precision Therapy"],"enrollment":39,"completionDate":"2028-07-10"},{"nctId":"NCT03385655","phase":"PHASE2","title":"Prostate Cancer Biomarker Enrichment and Treatment Selection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-08-01","conditions":["Prostate Cancer"],"enrollment":200,"completionDate":"2025-12-31"},{"nctId":"NCT04319783","phase":"PHASE2","title":"Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2021-06-02","conditions":["Advanced Prostate Carcinoma","Cancer of Prostate","PSA","Castrate Resistant Prostate Cancer"],"enrollment":65,"completionDate":"2026-06"},{"nctId":"NCT06401980","phase":"PHASE2","title":"Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-22","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":162,"completionDate":"2030-09"},{"nctId":"NCT05413421","phase":"PHASE1","title":"Study of ORIC-944 in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"ORIC Pharmaceuticals","startDate":"2022-06-01","conditions":["Metastatic Prostate Cancer"],"enrollment":250,"completionDate":"2026-09"},{"nctId":"NCT05202301","phase":"","title":"A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-15","conditions":["Prostate Cancer"],"enrollment":13779,"completionDate":"2025-07-15"},{"nctId":"NCT03568656","phase":"PHASE1,PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":["Metastatic Castration-Resistant Prostate Cancer","Metastatic Breast Cancer","Non-small Cell Lung Cancer","Advanced Solid Tumors"],"enrollment":220,"completionDate":"2025-07-06"},{"nctId":"NCT06625970","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-04-10","conditions":["High Risk Prostate Carcinoma","Prostate Cancer"],"enrollment":700,"completionDate":"2045-10"},{"nctId":"NCT07031258","phase":"","title":"Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-06","conditions":["Metastatic Hormone-sensitive Prostate Cancer","Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)"],"enrollment":50,"completionDate":"2027-06"},{"nctId":"NCT05171387","phase":"PHASE2","title":"Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-11-30","conditions":["Prostate Cancer"],"enrollment":78,"completionDate":"2025-02-24"},{"nctId":"NCT06013475","phase":"","title":"An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-08-31","conditions":["Non-metastatic Castration-resistant Prostate Cancer"],"enrollment":1375,"completionDate":"2024-10-28"},{"nctId":"NCT06992232","phase":"PHASE2","title":"Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-08-01","conditions":["Prostate Cancer Metastatic Disease"],"enrollment":144,"completionDate":"2028-07-31"},{"nctId":"NCT05694819","phase":"PHASE2","title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2020-04-17","conditions":["Salivary Gland Cancer"],"enrollment":56,"completionDate":"2026-03"},{"nctId":"NCT04925648","phase":"PHASE2","title":"Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction","status":"RECRUITING","sponsor":"St Vincent's Hospital, Sydney","startDate":"2021-10-18","conditions":["Metastatic Prostate Cancer"],"enrollment":22,"completionDate":"2025-12-01"},{"nctId":"NCT03314324","phase":"PHASE2","title":"A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-11-29","conditions":["Metastatic Castrate-resistant Prostate (CRPC) Cancer"],"enrollment":250,"completionDate":"2024-09-25"},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)","Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":750,"completionDate":"2026-12"},{"nctId":"NCT06190899","phase":"PHASE1,PHASE2","title":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Celcuity Inc","startDate":"2024-01-01","conditions":["mCRPC (Metastatic Castration-resistant Prostate Cancer)","Genital Diseases, Male","Urogenital Diseases, Male","Prostatic Disease","Prostatic Neoplasms, Castration-Resistant","Prostate Cancer"],"enrollment":54,"completionDate":"2027-11"},{"nctId":"NCT06652607","phase":"","title":"PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-12-20","conditions":["Prostate Cancer","Metastatic Cancer","Castrate Sensitive Prostate Cancer"],"enrollment":152,"completionDate":"2028-04-30"},{"nctId":"NCT06306612","phase":"NA","title":"CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-21","conditions":["Prostate Cancer"],"enrollment":192,"completionDate":"2028-12-31"},{"nctId":"NCT06446401","phase":"","title":"The Case of \"Triple\" Versus \"Double\" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-10-20","conditions":["Prostate Cancer"],"enrollment":1400,"completionDate":"2031-12-31"},{"nctId":"NCT06838520","phase":"","title":"Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-01","conditions":["Prostate Cancer (Adenocarcinoma)"],"enrollment":200,"completionDate":"2030-12-31"},{"nctId":"NCT05676203","phase":"PHASE3","title":"A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jena University Hospital","startDate":"2023-05-16","conditions":["Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":250,"completionDate":"2027-01"},{"nctId":"NCT05612880","phase":"","title":"Physical Function During ARSI Treatment","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-10-13","conditions":["Advanced Prostate Carcinoma"],"enrollment":24,"completionDate":"2024-11-06"},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":["Prostate Cancer Metastatic"],"enrollment":500,"completionDate":"2039-08-01"},{"nctId":"NCT06276465","phase":"PHASE3","title":"Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-10-07","conditions":["Prostatic Cancer, Castration-Resistant"],"enrollment":336,"completionDate":"2032-10-07"},{"nctId":"NCT04070209","phase":"PHASE2","title":"Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)","status":"RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2020-10-19","conditions":["Metastatic Prostate Cancer","Castration-resistant Prostate Cancer"],"enrollment":66,"completionDate":"2027-11"},{"nctId":"NCT03724747","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-18","conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"enrollment":63,"completionDate":"2024-10-31"},{"nctId":"NCT06498921","phase":"","title":"An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-07-15","conditions":["Metastatic Hormone-sensitive Prostate Cancer"],"enrollment":106,"completionDate":"2024-09-15"},{"nctId":"NCT04916613","phase":"PHASE3","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-04-19","conditions":["Prostate Cancer Metastatic"],"enrollment":300,"completionDate":"2037-09"},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":["Castration-resistant Prostate Cancer","Oligoprogressive"],"enrollment":246,"completionDate":"2029-01-20"}],"_emaApprovals":[{"date":"2020-03-27","status":"Authorised","company":"Bayer AG"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"NUBEQA"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"321167","NDDF":"018070","UNII":"X05U0N2RCO","VANDF":"4038612","INN_ID":"10227","RXNORM":"2180325","UMLSCUI":"C4547776","chemblId":"CHEMBL4297185","ChEMBL_ID":"CHEMBL4297185","KEGG_DRUG":"D11045","DRUGBANK_ID":"DB12941","PUBCHEM_CID":"67171867","SNOMEDCT_US":"789148001","IUPHAR_LIGAND_ID":"10439","MESH_SUPPLEMENTAL_RECORD_UI":"C000607739"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Bayer HealthCare Pharmaceuticals Inc.","brandName":"NUBEQA","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2019-","companyName":"Bayer Healthcare Pharmaceuticals Inc","relationship":"Original Developer"},{"period":"present","companyName":"Bayer Healthcare","relationship":"Current Owner"},{"period":"2020","companyName":"Bayer Yakuhin, Ltd","relationship":"PMDA Licensee"},{"period":"2020","companyName":"Bayer AG","relationship":"EMA Licensee"}],"publicationCount":513,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:58:43.322231+00","atcClassification":{"source":"DrugCentral","atcCode":"L02BB06","allCodes":["L02BB06"]},"biosimilarFilings":[],"originalDeveloper":"Bayer Healthcare Pharmaceuticals Inc","recentPublications":[{"date":"2026 Apr","pmid":"41895750","title":"Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer.","journal":"Anticancer research"},{"date":"2026 Mar 26","pmid":"41886076","title":"Vigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2026 Mar 18","pmid":"41851476","title":"Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.","journal":"Prostate cancer and prostatic diseases"},{"date":"2026 Mar 16","pmid":"41840025","title":"Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer.","journal":"Scientific reports"},{"date":"2026 Feb 28","pmid":"41815147","title":"Neoadjuvant androgen deprivation therapy with bicalutamide compared to hormonal agents in treating high-risk prostate cancer: a real-world cohort study.","journal":"Translational cancer research"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Bayer Healthcare","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"2019","enrichmentLevel":4,"visitCount":4,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-07-30T00:00:00.000Z","mah":"BAYER HEALTHCARE PHARMACEUTICALS INC","brand_name_local":null,"application_number":""},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-01-23T00:00:00.000Z","mah":"Bayer Yakuhin, Ltd","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-01-07T00:00:00.000Z","mah":"BAYER HEALTHCARE","brand_name_local":null,"application_number":"NDA212099"},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":35,"withResults":2},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:44:51.791326+00:00","fieldsConflicting":4,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}